Clinical Trials Browser

Phase 1/2 × Arginine × 90 days × Clear all

NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Phase 1/2 Recruiting

Meningioma